MRNA

Leaked Phase 3 INTerpath-001 melanoma data sent shares down 17.57% on October 22 despite a 42% recurrence risk cut.

Leaked Phase 3 melanoma data showed a 0.58 hazard ratio, short of the 0.51 investors expected, and the stock fell 17.57%.

Phase 3 melanoma data leaked before ESMO, showing a 42% cut in recurrence or death, and the stock fell 17.57%.

Shares rose 6.69% to $242.08 on pre-data buying ahead of the Phase 3 INTerpath-001 melanoma presentation at ESMO.

Shares fell 7.82% to $218.01 on 16 October as profit-taking hit the stock that had risen furthest on the cancer-vaccine rally.

Shares rose 14.21% on 9 October after a New York Times report on an NIH cancer vaccine initiative and Nasdaq-100 inclusion.

Shares rose 14.21% on 9 October after a reported $200 million NIH cancer-vaccine initiative and Nasdaq-100 entry.

NIH-backed $200 million cancer vaccine initiative report lifted shares 14.21% to $225.00 on 9 October.

Shares fell 5.00% to $213.74 on likely profit-taking after the 14.21% October 9 rally and Nasdaq-100 entry, with no company news.

Nasdaq-100 re-entry and an NYT report on an NIH cancer vaccine partnership drove a 14.21% jump to $225.00 on 9 October.

Moderna stock fell 7.75% due to sell-the-news profit taking after Nasdaq-100 inclusion news, valuation downgrades, and pre-ESMO de-risking.

Moderna stock surged due to forced-buying ahead of its Nasdaq-100 re-inclusion and expansion updates on its mRNA oncology platform.

Moderna dropped after Citigroup and Redburn downgraded the stock to Sell over valuation concerns and an adverse patent court ruling.

Moderna surged after ESMO selected late-breaking data for its cancer vaccine, alongside FDA clearances and a $2.6B debt offering.

Moderna shares surged after its Phase 3 melanoma vaccine data secured a Presidential Symposium slot at ESMO, alongside an analyst upgrade.

Moderna shares surged after confirming Phase 3 cancer vaccine data presentation at ESMO alongside regulatory approvals and upgrades.

Moderna stock surged after Phase 3 data for its cancer vaccine was selected for an ESMO Presidential Symposium.

Moderna secured a top ESMO presentation slot for Phase 3 cancer vaccine data, driving analyst target upgrades and investor optimism.

Moderna confirmed its Phase 3 personalized mRNA cancer vaccine data was selected for a Presidential Symposium presentation at ESMO.

Moderna stock rose after abstracts for its mRNA cancer vaccine were selected for presentation at the ESMO Congress 2026.

Moderna stock surged following positive conference presentations, a technical breakout, short covering, and Phase 3 cancer vaccine results.

Moderna closed an upsized $3.0B offering of zero-coupon convertible senior notes paired with capped calls to limit equity dilution.

The stock dropped 5.77% due to valuation-driven profit-taking after a massive rally sparked by Phase 3 cancer vaccine trial data.

Moderna shares surged due to Wall Street analyst upgrades and price target hikes following positive Phase 3 cancer trial results.

Moderna announced positive Phase 3 trial results for its personalized mRNA cancer vaccine combined with Keytruda in melanoma patients.

Moderna and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine in high-risk melanoma patients.

Moderna fell 23.55% on profit-taking and valuation resets after a 177% rally driven by Phase 3 cancer vaccine trial results.

Moderna announced positive Phase 3 trial data for its mRNA cancer vaccine combined with Keytruda in treating melanoma.

Moderna surged after FDA approval of its mRNA flu vaccine, a Q2 earnings beat, and a $200 million reduction in operating expenses.

Moderna stock surged due to FDA approval of its mRNA flu vaccine, a Q2 earnings beat, reduced expense guidance, and institutional buying.

Moderna shares surged after the FDA approved mFLUSIVA, the first mRNA-based seasonal influenza vaccine authorized in the U.S.

Moderna fell due to escalating patent litigation with Sanofi and CureVac, valuation concerns ahead of Q2 earnings, and insider selling.

Moderna fell due to Danaher's weak earnings dragging biotechs lower, pre-catalyst investor de-risking, and new patent litigation.

The stock fell due to Wall Street downgrades, pre-earnings de-risking, high valuation multiples, and a looming $950M settlement payment.

JPMorgan placed MRNA on its Top Short Ideas list due to valuation over-expansion, cash burn, and a missed flu contracting window.

The stock fell due to negative analyst notes from JPMorgan and Morgan Stanley alongside a $950 million patent settlement payout.

Moderna fell due to a JP Morgan Sell rating, slashed Q2 revenue guidance, and a $950 million patent settlement cash outflow.

Moderna fell due to a JPMorgan short call, lowered respiratory vaccine guidance, and a $950 million patent litigation payout.

JPMorgan reaffirmed its Sell rating on Moderna and added the stock to its Q3 2026 Tactical Short List.

Morgan Stanley reiterated a Neutral rating with a $39 price target, sparking profit-taking over valuation concerns.

The stock surged following a unanimous FDA advisory committee vote recommending approval for its mFlusiva seasonal mRNA flu vaccine.

The stock surged due to high FDA approval odds for its flu vaccine candidate mRNA-1010, pipeline updates, and an analyst upgrade.

Shares surged after a 9-0 FDA Advisory Committee vote backed its flu vaccine and a Science Day presentation revealed a new pipeline.

Moderna stock surged following a unanimous 9-0 FDA panel endorsement for its flu vaccine and a strategic Science Day pipeline presentation.